PBPH vs. IDNA
PBPH (Portfolio Building Block World Pharma and Biotech Index ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds - PBPH tracks the BITA Global Pharma and Biotech Select Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. A 0.66 correlation means they provide meaningful diversification when combined. PBPH charges 0.13%/yr vs 0.47%/yr for IDNA.
Performance
PBPH vs. IDNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PBPH achieves a 2.63% return, which is significantly lower than IDNA's 19.52% return.
PBPH
- 1D
- 1.41%
- 1M
- 0.87%
- YTD
- 2.63%
- 6M
- 2.11%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
IDNA
- 1D
- 1.53%
- 1M
- 6.29%
- YTD
- 19.52%
- 6M
- 16.84%
- 1Y
- 54.42%
- 3Y*
- 11.16%
- 5Y*
- -8.18%
- 10Y*
- —
PBPH vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
PBPH Portfolio Building Block World Pharma and Biotech Index ETF | 2.63% | 0.74% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 19.52% | -1.59% |
Correlation
The correlation between PBPH and IDNA is 0.66, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (All Time) Calculated using the full available price history since Nov 25, 2025 | 0.66 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PBPH vs. IDNA — Risk / Return Rank
PBPH
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
IDNA
PBPH vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PBPH | IDNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.34 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 5.13 | — |
| Martin ratioReturn relative to average drawdown | — | 14.30 | — |
Loading charts...
Drawdowns
PBPH vs. IDNA - Drawdown Comparison
The maximum PBPH drawdown since its inception was -11.10%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for PBPH and IDNA.
Loading charts...
Drawdown Indicators
| PBPH | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -11.10% | -68.26% | +57.16% |
Max Drawdown (1Y)Largest decline over 1 year | — | -10.66% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -29.46% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -68.26% | — |
Current DrawdownCurrent decline from peak | -5.21% | -41.07% | +35.86% |
Average DrawdownAverage peak-to-trough decline | -4.36% | -36.28% | +31.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 3.82% | — |
Volatility
PBPH vs. IDNA - Volatility Comparison
Loading charts...
Volatility by Period
| PBPH | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 7.33% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 18.45% | — |
Volatility (1Y)Calculated over the trailing 1-year period | 17.07% | 24.96% | -7.89% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 17.07% | 28.47% | -11.40% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 17.07% | 29.51% | -12.44% |
PBPH vs. IDNA - Expense Ratio Comparison
PBPH has a 0.13% expense ratio, which is lower than IDNA's 0.47% expense ratio.
Dividends
PBPH vs. IDNA - Dividend Comparison
PBPH's dividend yield for the trailing twelve months is around 0.09%, less than IDNA's 0.90% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 0.90% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
PBPH Portfolio Building Block World Pharma and Biotech Index ETF | 0.09% | 0.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
PBPH and IDNA have a correlation of 0.66, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, PBPH is cheaper at 0.13% per year. The better choice depends on whether you care most about return, fees, risk, or income.
PBPH is cheaper with a 0.13% expense ratio, compared with 0.47% for IDNA.
IDNA has the higher dividend yield at 0.90%, compared with 0.09% for PBPH.
PBPH tracks BITA Global Pharma and Biotech Select Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: Portfolio Building Block and iShares. Their fees differ too: 0.13% for PBPH and 0.47% for IDNA.
Find the right allocation for PBPH and IDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer